Navigation Links
Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Date:5/28/2008

ProLindac Demonstrates Sustained and Significant Reductions in Cancer

Market CA-125

DALLAS, May 28 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that the company gave an invited oral presentation on its lead anticancer compound, ProLindac(TM) at the International Symposium on Polymer Therapeutics: Laboratory to Clinical Practice, taking place from May 26-28 in Valencia, Spain. The presentation was entitled "Promising Safety and Efficacy Results from an Ongoing Clinical Study of ProLindac in Recurrent Ovarian Cancer." ProLindac is Access' novel DACH platinum-polymer prodrug, which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials.

The invited presentation was given by Professor Esteban Cvitkovic, M.D., Access Pharmaceuticals' Senior Director, Clinical Oncology R&D. Professor Cvitkovic presented data from the ongoing Phase 2 monotherapy clinical study of ProLindac in patients with recurrent ovarian cancer. In two dosing regimens, ProLindac was given once every two weeks and once every three weeks. During the last and highest dose levels explored, sustained and significant reductions in the specific serum market Ca-125 were seen over multiple dosings in several patients. ProLindac was well-tolerated with minimal side-effects.

"We continue to be impressed by clinical results that indicate a significant DACH platinum drug effect with a very benign side effect profile," stated Jeffrey B. Davis, Access' President & CEO. "The sustained efficacy and minimal toxicity seen over multiple dosings provides further evidence that ProLindac has the potential to become a very important anticancer agent in the future. We are finalizing our plans for Phase 2 combination trials where we intend to look at multiple solid tumor types with ProLindac in combination with other cancer agents, like taxol and gemcitabine."


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
2. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
10. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
11. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... agreement with Patterson Veterinary Supply. Patterson ... of Abaxis veterinary products throughout the United ...
(Date:10/1/2014)... DIEGO , Oct. 1, 2014  ResMed (NYSE: ... sleep and the first company to design complete sleep apnea ... educate women about the importance of a good night,s sleep. ... will challenge the myth that feeling tired is just part ... understand that sleep is a critical pillar of health, essential ...
(Date:10/1/2014)...   Cypher Genomics, Inc., the genome informatics ... Ravenel as chief technology officer. Ravenel has more ... and a proven track record of designing and architecting ... has been recognized as a top designer and architect ... industry-wide for delivering innovative products that operate at scale ...
Breaking Medicine Technology:Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2
... Romark Laboratories, L.C., a,privately-owned biopharmaceutical company, today ... clinical trial to evaluate the safety and,efficacy of ... in,U.S. patients with chronic hepatitis C genotype 1 ... of care therapy (peginterferon and,ribavirin). The company expects ...
... Urologist Presents OrBIT Study Results Comparing Percutaneous, Tibial Nerve ... ... Meeting, MINNEAPOLIS, May 21 Uroplasty, Inc. (Amex:,UPI), ... proprietary products for the treatment of voiding dysfunction,today highlighted ...
Cached Medicine Technology:Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 2Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 3
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product manufacturer and retailer. ... the global customers in the past few years. Now, ... items. All its online workers are professional and patient; ... The company has recently added a new assortment of ... company’s marketing specialist has announced that all these brand ...
(Date:10/2/2014)... News) -- Children with autism are more sedentary than ... being more active, a small study suggests. Researchers ... some with autism and some without. Children with autism ... activity and 70 more minutes each day sitting than ... scored lower on strength, but had similar body-mass index ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... and the District of Columbia now have a total of ... that has been infecting children since the summer, U.S. ... virus have died in recent weeks, but it,s not clear ... those deaths, officials said. Health officials are also trying ...
(Date:10/1/2014)... today in the Journal of the American Medical ... years with moderate or severe chronic knee pain, acupuncture ... University of Melbourne randomly assigned 282 patients (50 years ... or sham or pretend laser treatment. , Treatments ... blinded to laser and sham (inactive) laser acupuncture. , ...
(Date:10/1/2014)... the adage that encourages people to keep their "eyes ... comes to exercise. When walking, staying focused on a ... appear shorter and help people walk there faster, psychology ... to walking while looking around the environment naturally, offers ... , "People are less interested in exercise if physical ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... a recent study in the journal Obesity Research. Body fat ... //tissues are of two types- subcutaneous fat and visceral fat. ... may make the people more at risk to prostate cancer. ... same number of healthy counterparts by assessing their body fat ...
... air pollution due to combustion has been proved to cause ... The research was done by Columbia Center for Children’s Environmental ... Columbia University, US. ,The researchers had observed the ... aromatic hydrocarbons (PAH) that can penetrate placenta to affect the ...
... past have suggested early onset wheezing is associated with ... bronchial hyper-responsiveness. Children with the longest duration of wheezing ... children who develop wheeze later in childhood end up ... early. ,This study involved nearly 1,500 children born ...
... a herb used in traditional Indian medicine to treat ... // in a manner similar to prescription drugs. ... salacia oblonga, which is native to regions of India ... that break down carbohydrates in the body. These enzymes ...
... Pseudomonas aeruginosa is a potentially life-threatening infection for ... doctors often prescribe an inhaled drug called colistin ... drug is controversial because some patients experience chest ... severe coughing and reduced lung function. However a ...
... New research shows children younger than age 1 can learn certain ... // in one context and understand them in another, researchers worked ... ,The parents used 12 board books and a set of 48 ... and chairs in simple games with their children. The games were ...
Cached Medicine News:
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
...
Designed for stab incisions...
Medicine Products: